Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582100 · ClinicalTrials.gov registry record · NA
Reletex for Nausea in GERD Patients
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01582100 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT01582100, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Gastroesophageal reflux disease (GERD) is a highly prevalent condition that is frequently encountered in the health care setting. It affects roughly 40% of Americans monthly and 10% weekly. Of those with GERD, there exists a cohort that experience nausea with or without vomiting that is unresponsive to PPI's and anti-emetics. For these patients, treatment options are limited and these symptoms may substantially alter their quality of life. New and novel therapies emerging include neuromodulation devices that may affect the central pathways leading to these symptoms. Of these, the Reletex band has been tested and proven efficacious in the treatment of nausea and vomiting associated with pregnancy, chemotherapy, and surgery, in addition to standard anti-nausea medications. The investigators propose that through a similar mechanism, this device as an adjunct to PPI's and anti-emetics will reduce GERD-associated the nausea with or without vomiting, and by so doing, improve the quality of lives in this patient population.
Interventions
- DEVICE Reletex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582100
The ClinicalTrials.gov registry entry for NCT01582100 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reletex is the first listed.
NCT01582100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582100 about?
NCT01582100 is a clinical study titled "Reletex for Nausea in GERD Patients". Gastroesophageal reflux disease (GERD) is a highly prevalent condition that is frequently encountered in the health care setting. It affects roughly 40% of Americans monthly and 10% weekly. Of those with GERD, there exists a cohort that experience nausea with or without vomiting that is unresponsive...
What is the current status of trial NCT01582100?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2012-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01582100?
The interventions under investigation include: Reletex (DEVICE).
Who is sponsoring clinical trial NCT01582100?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.